调节性B细胞在多发性骨髓瘤中的研究进展

doi:DOI：10.3877/cma.j.issn.2095-655X.2024.02.013

摘要
图/表
参考文献
相关文章 (0)

全文: PDF (424 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要多发性骨髓瘤（MM）是一种骨髓浆细胞恶性增殖性疾病。免疫抑制性微环境是导致MM患者抗肿瘤免疫监视功能受损，恶性浆细胞免疫逃逸的重要机制之一。调节性免疫细胞被认为是免疫抑制性微环境的重要组成部分，其中调节性B细胞（Bregs）是近年来发现的一种特殊类型的B细胞，可通过分泌多种抑制性可溶性细胞因子及与细胞间直接接触而发挥免疫抑制作用。MM骨髓微环境中Bregs的比例升高，可能通过分泌IL-10、抑制自然杀伤细胞功能等机制参与免疫抑制性骨髓微环境的形成，进而影响MM的治疗反应和预后，Bregs有望成为MM的潜在免疫治疗靶点。笔者主要就Bregs 的表型、来源、免疫调节机制及其在MM中的研究进展进行综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ： B淋巴细胞, 调节性, 多发性骨髓瘤, 肿瘤微环境, 免疫调节

Abstract：Multiple myeloma (MM) is a malignant proliferative disorder of bone marrow plasma cells. Suppressive immune microenvironment is one of the important mechanisms for the impaired anti-tumor immune surveillance in MM patients, leading to the immune escape of malignant plasma cells. Regulatory immune cells are considered to be an important part of the suppressive immune microenvironment, and regulatory B cells (Bregs), as a special type of B cells discovered in recent years, can exert immunosuppressive effects mainly through the secretion of various inhibitory soluble cytokines and direct contact with cells. The increased proportion of Bregs in the bone marrow microenvironment of MM may participate in the formation of immunosuppressive bone marrow microenvironment by screting IL-10 and inhibiting the function of natural killer cells, thereby affecting the therapeutic response and prognosis of MM, so Bregs is expected to become a potential immunotherapeutic target of MM. This article mainly reviews the phenotype, source, immunomodulatory mechanisms and research progress of Bregs in MM.

Key words： B-lymphocytes, regulatory Multiple myeloma Tumor microenvironment Immunoregulation

收稿日期: 2023-11-05

基金资助:山东省自然科学基金（ZR2020MH207，ZR2020MH251）

通讯作者: 孙道萍， Email: xinyingping@163.com

引用本文:

陆天孙道萍. 调节性B细胞在多发性骨髓瘤中的研究进展[J]. 中华诊断学电子杂志, 2024, 12(2): 133-137.
Lu Tian1, Sun Daoping2. Research progress of regulatory B cells in multiple myeloma. zhzdx, 2024, 12(2): 133-137.

链接本文:

http://www.zhzdxzz.com/CN/DOI：10.3877/cma.j.issn.2095-655X.2024.02.013 或 http://www.zhzdxzz.com/CN/Y2024/V12/I2/133

［1］Boussi LS，Avigan ZM，Rosenblatt J.Immunotherapy for the treatment of multiple myeloma［J］.Front Immunol，2022 (13)：1027385.DOI：10.3389/fimmu.2022.1027385. ［2］Zhang L，Tai YT，Ho M，et al.Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu［J］.Blood Cancer J，2017，7(3)：e547.DOI：10.1038/bcj.2017.24. ［3］Bartosińska J，Purkot J，Karczmarczyk A，et al.Differential function of a novel population of the CD19+CD24hiCD38hi Bregs in psoriasis and multiple myeloma［J］.Cells，2021，10(2)：411.DOI：10.3390/cells10020411. ［4］Tang W，Li Y，Zou Z，et al.A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma［J］.Cancer Med，2023，12(3)：3054-3067.DOI：10.1002/cam4.5228. ［5］Wang L，Fu Y，Chu Y.Regulatory B Cells［J］.Adv Exp Med Biol，2020(1254)：87-103.DOI：10.1007/978-981-15-3532-1_8. ［6］Michaud D，Steward CR，Mirlekar B，et al.Regulatory B cells in cancer［J］.Immunol Rev，2021，299(1)：74-92.DOI：10.1111/imr.12939. ［7］Yanaba K，Bouaziz JD，Haas KM，et al.A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses［J］.Immunity，2008，28(5)：639-650.DOI：10.1016/j.immuni.2008.03.017. ［8］Zhang Y， Li J， Zhou N， et al. The unknown aspect of BAFF：inducing IL-35 production by a CD5+CD1dhiFcγRIIbhi regulatory B-cell subset in lupus［J］.J Invest Dermatol，2017，137(12)：2532-2543.DOI：10.1016/j.jid.2017.07.843. ［9］Lundy SK，Fox DA.Reduced Fas ligand-expressing splenic CD5+ B lymphocytes in severe collagen-induced arthritis［J］.Arthritis Res Ther，2009，11(4)：R128.DOI：10.1186/ar2795. ［10］Shalapour S，Font-Burgada J，Di Caro G，et al.Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy［J］.Nature，2015，521(7550)：94-98.DOI：10.1038/nature14395. ［11］Xu L， Liu X， Liu H， et al. Impairment of granzyme B-producing regulatory B Cells correlates with exacerbated rheumatoid arthritis［J］.Front Immunol，2017(8)：768.DOI：10.3389/fimmu.2017.00768. ［12］Meng L，Almeida LN，Clauder AK，et al.Bone marrow plasma cells modulate local myeloid-lineage differentiation via IL-10［J］.Front Immunol，2019(10):1183.DOI：10.3389/fimmu.2019.01183. ［13］Wang L，Fu Y，Chu Y.Regulatory B Cells［J］.Adv Exp Med Biol，2020(1254)：87-103.DOI：10.1007/978-981-15-3532-1_8. ［14］Rosser EC， Mauri C. Regulatory B cells：origin，phenotype，and function［J］.Immunity，2015，42(4)：607-612.DOI：10.1016/j.immuni.2015.04.005. ［15］Lino AC，Dang VD，Lampropoulou V，et al.LAG-3 inhibitory receptor expression identifies immunosuppressive natural regulatory plasma cells［J］.Immunity，2018，49(1)：120-133.e9.DOI：10.1016/j.immuni.2018.06.007. ［16］Catalán D， Mansilla MA， Ferrier A， et al. Immunosuppressive mechanisms of regulatory B Cells［J］.Front Immunol，2021(12)：611795.DOI:10.3389/fimmu.2021.611795. ［17］Lee KM，Stott RT，Zhao G，et al.TGF-β-producing regulatory B cells induce regulatory T cells and promote transplantation tolerance［J］.Eur J Immunol，2014，44(6)：1728-1736.DOI：10.1002/eji.201344062. ［18］Bodogai M，Moritoh K，Lee-Chang C，et al.Immunosuppressive and prometastatic functions of myeloid-derived suppressive cells rely upon education from tumor-associated B Cells［J］.Cancer Res，2015，75(17)：3456-3465.DOI：10.1158/0008-5472.CAN-14-3077. ［19］Dambuza IM，He C，Choi JK，et al.IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease［J］.Nat Commun，2017，8(1)：719.DOI：10.1038/s41467-017-00838-4. ［20］Abebe EC，Dejenie TA，Ayele TM，et al.The role of regulatory B cells in health and diseases：a systemic review［J］.J Inflamm Res，2021(14)：75-84.DOI：10.2147/JIR.S286426. ［21］Oleinika K，Rosser EC，Matei DE，et al.CD1d-dependent immune suppression mediated by regulatory B cells through modulations of iNKT cells［J］.Nat Commun，2018，9(1)：684.DOI：10.1038/s41467-018-02911-y. ［22］Chen Y，Li C，Lu Y，et al.IL-10-producing CD1dhiCD5+ regulatory B Cells may play a critical role in modulating immune homeostasis in silicosis patients［J］.Front Immunol，2017(8):110.DOI：10.3389/fimmu.2017.00110. ［23］Bosma A，Abdel-Gadir A，Isenberg DA，et al.Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells［J］.Immunity，2012，36(3)：477-490.DOI:10.1016/j.immuni.2012.02.008. ［24］Ding Q，Yeung M，Camirand G，et al.Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice［J］.J Clin Invest，2011，121(9)：3645-3656.DOI：10.1172/JCI46274. ［25］Cherukuri A，Mohib K，Rothstein DM.Regulatory B cells：TIM-1，transplant tolerance，and rejection［J］.Immunol Rev，2021，299(1)：31-44.DOI：10.1111/imr.12933. ［26］Aravena O， Ferrier A， Menon M， et al. TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients［J］.Arthritis Res Ther，2017，19(1)：8.DOI:10.1186/s13075-016-1213-9. ［27］Ma L，Liu B，Jiang Z，et al.Reduced numbers of regulatory B cells are negatively correlated with disease activity in patients with new-onset rheumatoid arthritis［J］.Clin Rheumatol，2014，33(2)：187-195.DOI:10.1007/s10067-013-2359-3. ［28］Xiao S， Bod L， Pochet N， et al. Checkpoint receptor TIGIT expressed on Tim-1+ B Cells regulates tissue inflammation［J］.Cell Rep，2020，32(2)：107892.DOI：10.1016/j.celrep.2020.107892. ［29］Xiao X，Lao XM，Chen MM，et al.PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression［J］.Cancer Discov，2016，6(5)：546-559.DOI：10.1158/2159-8290.CD-15-1408. ［30］Wang X，Wang G，Wang Z，et al.PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1/PD-L1-dependent pathway［J］.Mol Immunol，2019(109)：20-26.DOI：10.1016/j.molimm.2019.02.009. ［31］Khan AR，Hams E，Floudas A，et al.PD-L1hi B cells are critical regulators of humoral immunity［J］.Nat Commun，2015(6)：5997.DOI：10.1038/ncomms6997. ［32］Jiao Y， Yi M， Xu L， et al. CD38：targeted therapy in multiple myeloma and therapeutic potential for solid cancers［J］.Expert Opin Investig Drugs，2020，29(11)：1295-1308.DOI：10.1080/13543784.2020.1814253. ［33］Swamydas M，Murphy EV，Ignatz-Hoover JJ，et al.Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma［J］.J Hematol Oncol，2022，15(1)：17.DOI：10.1186/s13045-022-01234-2. ［34］Uckun FM.Overcoming the immunosuppressive tumor microenvironment in multiple myeloma［J］.Cancers (Basel)，2021，13(9):2018.DOI：10.3390/cancers13092018. ［35］Tai YT，Lin L，Xing L，et al.APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma：therapeutic implications［J］.Leukemia，2019，33(2)：426-438.DOI：10.1038/s41375-018-0242-6. ［36］Alexandrakis MG， Goulidaki N， Pappa CA， et al. Interleukin-10 induces both plasma cell proliferation and angiogenesis in multiple myeloma［J］.Pathol Oncol Res，2015，21(4)：929-934.DOI：10.1007/s12253-015-9921-z. ［37］Michaud D，Steward CR，Mirlekar B，et al.Regulatory B cells in cancer［J］.Immunol Rev，2021，299(1)：74-92.DOI：10.1111/imr.12939. ［38］Cui J，Zou Z，Duan J，et al.Predictive values of PET/CT in combination with regulatory B Cells for therapeutic response and survival in contemporary patients with newly diagnosed multiple myeloma［J］.Front Immunol，2021(12)：671904.DOI：10.3389/fimmu.2021.671904. ［39］Prabhala R，Samur MK，Talluri S，et al.Favorable progression-free survival associated with immune bio-markers modulated by pomalidomide in relapsed/refractory multiple myeloma：an analysis of phase III study［J］.Blood，2019，134 (Supplement_1)：1784.DOI:10.1182/blood-2019-131257.